Abstract
The occurrence of radiation necrosis to the extravasation of therapeutic radionuclide—yttrium-90-ibritumomab tiuxetan—is described, as well as the subsequent steps taken to both address the occurrence and to prevent the reoccurrence of such an adverse event. Published reports on the extravasation of diagnostic and therapeutic radionuclides are reviewed, as are prevention and treatment protocols.
Get full access to this article
View all access options for this article.